Loading provider…
Loading provider…
Hematology & Oncology Physician in San Diego, CA
NPI: 1245391242Primary Employer
UCSD Medical Group
health.ucsd.edu
HQ Phone
Get M.D. Sarah's Phone Numberphone_androidMobile
Get M.D. Sarah's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2003 - 2027

American Board of Internal Medicine
Medical Oncology
The Johns Hopkins University School of Medicine
hopkinsmedicine.org
Medical School
Until 2001
University of California (San Diego) Medical Center
Fellowship • Hematology and Medical Oncology
2005 - 2008
UCLA David Geffen School of Medicine/UCLA Medical Center
Residency • Internal Medicine
2001 - 2004
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 93 | 155 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 39 | 133 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 12 | 13 |
Pelvic mass after prostatectomy. Pseudosarcomatous fibromyxoid tumor.
Authors: Grigorian, Areg, Ponsford Tipps, Ann M, Derweesh, Ithaar H, Boles, Sarah G, Sicklick, Jason K
Journal: JAMA Surg
Efficacy of a web-based women’s health survivorship care plan for young breast cancer survivors: a randomized controlled trial
Authors: Jun Mao, Brian Kwan, Michael Krychman, Hui-Chun Su
Publication Date: 2019-05
Authors: Teresa Helsten, Richard Schwab, Rupa Subramanian, Barbara Parker
Journal: J Oncol Pract
Publication Date: 2015-08-04
Lead Sponsor: Seagen Inc.
Intervention / Treatment: DRUG: Trastuzumab, DRUG: ladiratuzumab vedotin
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Doxorubicin, DRUG: Olaratumab